Table 2.
Descriptive statistics among invasive female breast carcinoma cases (n = 270,124) in SEER's 13 Registry Database, diagnosed during the years 1992 to 2002
| All breast cancer cases minus IBC | Comprehensive IBC | |||||||||||
| Frequency (n) | 264,987 | 5,137 | ||||||||||
| % of total cases | 98.1% | 1.9% | ||||||||||
| Mean age (yrs) | 61.9 | 58.7 | ||||||||||
| Median age (yrs) | 62 | 57 | ||||||||||
| Mean size (cm) | 2.2 | 8.6 | ||||||||||
| Median size (cm) | 1.7 | 9.98 | ||||||||||
| Rate (SE) | 129.9 (0.3) | 2.5 (0.035) | ||||||||||
| n | % | Rate | RR | 95% CI | n | % | Rate | RR | 95% CI | |||
| Tumor size | ||||||||||||
| ≤ 2.0 centimeters | 151,723 | 56.2% | 74.6 | 1.0 | LL | UL | 102 | 2.0% | 0.1 | 1.0 | LL | UL |
| > 2.0 centimeters | 84,638 | 31.3% | 41.4 | 0.6 | 0.5 | 0.6 | 660 | 12.8% | 0.3 | 6.4 | 5.2 | 8.0 |
| Other or unknown | 28,626 | 10.6% | ∼ | ∼ | ∼ | ∼ | 4,375 | 85.2% | ∼ | ∼ | ∼ | ∼ |
| Lymph nodes | ||||||||||||
| LN negative | 163,153 | 60.4% | 80.2 | 1.0 | LL | UL | 547 | 10.6% | 0.3 | 1.0 | LL | UL |
| LN positive | 74,454 | 27.6% | 36.8 | 0.5 | 0.5 | 0.5 | 2,850 | 55.5% | 1.4 | 5.2 | 4.7 | 5.7 |
| Other or unknown | 27,380 | 10.1% | ∼ | ∼ | ∼ | ∼ | 1,740 | 33.9% | ∼ | ∼ | ∼ | ∼ |
| AJCC stage | ||||||||||||
| Stage I | 117,421 | 43.5% | 57.8 | 1.0 | LL | UL | 0 | 0.0% | ∼ | ∼ | LL | UL |
| Stage II | 91,777 | 34.0% | 45.2 | 0.8 | 0.8 | 0.8 | 0 | 0.0% | ∼ | ∼ | ∼ | ∼ |
| Stage III | 13,429 | 5.0% | 6.6 | 0.1 | 0.1 | 0.1 | 3,724 | 72.5% | ∼ | ∼ | ∼ | ∼ |
| Stage IV | 10,327 | 3.8% | 5.0 | 0.1 | 0.1 | 0.1 | 1,190 | 23.2% | ∼ | ∼ | ∼ | ∼ |
| Other or unknown | 32,033 | 11.9% | ∼ | ∼ | ∼ | ∼ | 223 | 4.3% | ∼ | ∼ | ∼ | ∼ |
| Tumor grade | ||||||||||||
| Low | 133,017 | 49.2% | 65.3 | 1.0 | LL | UL | 1,024 | 19.9% | 0.5 | 1.0 | LL | UL |
| High | 84,872 | 31.4% | 41.7 | 0.6 | 0.6 | 0.6 | 2,865 | 55.8% | 1.4 | 2.8 | 2.6 | 3.0 |
| Other or unknown | 47,098 | 17.4% | ∼ | ∼ | ∼ | ∼ | 1,248 | 24.3% | ∼ | ∼ | ∼ | ∼ |
| Pathology | ||||||||||||
| Duct NST | 183,740 | 68.0% | 90.3 | 1.00 | LL | UL | 1,429 | 27.8% | 0.70 | 1.00 | LL | UL |
| Tubular | 4,406 | 1.6% | 2.2 | 0.02 | 0.02 | 0.03 | 1 | 0.0% | 0.00 | 0.00 | 0.0 | 0.0 |
| Lobular | 21,651 | 8.0% | 10.6 | 0.12 | 0.12 | 0.12 | 195 | 3.8% | 0.10 | 0.13 | 0.1 | 0.2 |
| Medullary | 2,613 | 1.0% | 1.3 | 0.01 | 0.01 | 0.01 | 6 | 0.1% | 0.00 | 0.00 | 0.0 | 0.0 |
| Inflammatory | 0 | 0.0% | ∼ | ∼ | ∼ | ∼ | 3,004 | 58.5% | 1.48 | 2.10 | 2.0 | 2.2 |
| Papillary | 1,671 | 0.6% | 0.8 | 0.01 | 0.01 | 0.01 | 7 | 0.1% | 0.00 | 0.00 | 0.0 | 0.0 |
| Mucinous | 6,861 | 2.5% | 3.3 | 0.04 | 0.04 | 0.04 | 20 | 0.4% | 0.01 | 0.01 | 0.0 | 0.0 |
| Paget's disease | 1,999 | 0.7% | 1.0 | 0.01 | 0.01 | 0.01 | 27 | 0.5% | 0.01 | 0.02 | 0.0 | 0.0 |
| Comedocarcinoma | 4,459 | 1.7% | 2.2 | 0.02 | 0.02 | 0.03 | 18 | 0.4% | 0.01 | 0.01 | 0.0 | 0.0 |
| Other or unknown | 37,587 | 13.9% | ∼ | ∼ | ∼ | ∼ | 430 | 8.4% | ∼ | ∼ | ∼ | ∼ |
| ER | ||||||||||||
| ER positive | 162,467 | 60.1% | 79.8 | 1.0 | LL | UL | 1,977 | 38.5% | 1.0 | 1.0 | LL | UL |
| ER negative | 47,251 | 17.5% | 23.3 | 0.3 | 0.3 | 0.3 | 1,654 | 32.2% | 0.8 | 0.8 | 0.8 | 0.8 |
| Other or unknown | 55,269 | 20.5% | ∼ | ∼ | ∼ | ∼ | 1,506 | 29.3% | ∼ | ∼ | ∼ | ∼ |
| PR | ||||||||||||
| PR positive | 135,906 | 50.3% | 66.8 | 1.0 | LL | UL | 1,611 | 31.4% | 0.8 | 1.0 | LL | UL |
| PR negative | 66,878 | 24.8% | 32.9 | 0.5 | 0.5 | 0.5 | 1,933 | 37.6% | 1.0 | 1.2 | 1.1 | 1.3 |
| Other or unknown | 62,203 | 23.0% | ∼ | ∼ | ∼ | ∼ | 1,593 | 31.0% | ∼ | ∼ | ∼ | ∼ |
Key: Comprehensive IBC (i.e., IBC = ICD-O 8530 or EOD 70 or EOD 998); Rate, age-adjusted incidence rate expressed per 100,000 woman-years; RR, rate ratio where a given characteristic is compared to a referent value with an assigned RR of 1.0; 95% CI, 95% confidence interval with lower and upper bounds; ∼, statistic not calculated; AI/AN, American Indian or Alaska Native; API, Asain or Pacific Islander; Duct NST, ductal carcinoma of no special type or not othewise specified; ER, estrogen receptor; PR, progesterone receptor.